Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trialGlenda Gray, Mookho Malahleha, Philipp Mann et al.|The Lancet Infectious Diseases|2024Cited by 40
Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trialK. Rachael Parks, M. Juliana McElrath, Zoe Moodie et al.|Science Translational Medicine|2025Cited by 40
Use of 3M-052-AF with Alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodiesM. Juliana McElrath, K. Rachael Parks, Mingchao Shen et al.|The Journal of Experimental Medicine|2024Cited by 28
A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is VaccinatedDean Follmann, Kathleen M. Neuzil, Jonathan Fintzi et al.|Annals of Internal Medicine|2021Cited by 26
Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy TrialsDean Follmann, Kathleen M. Neuzil, Jonathan Fintzi et al.|medRxiv|2020Cited by 25